Valeant Pharmaceuticals May Restate Earnings After Board Review |
| February 23, 2016 | February 2016 Bond Updates |
|
Valeant Pharmaceuticals may restate its financial results, according to a report from the Wall Street Journal. |
| View more at: http://www.forbes.com/sites/antoinegara/2016/02/22/valeant-pharmaceuticals-may-restate-earnings-after-board-review/ |
| Related News |
|